Abstract
BackgroundReFIRST is an exploratory, multi-center, open label, uncontrolled phase IIIb study evaluating the efficacy of re-treatment with Rituximab (RTX). It is the extension of the FIRST study that included 302...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have